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Patients with end stage renal failure (ESRF) have an increased
risk of premature cardiovascular disease. Left ventricular (LV)
abnormalities, so called ‘uremic cardiomyopathy’, are
associated with poorer outcome. Cardiac magnetic resonance
imaging (CMR) accurately defines LV dimensions and identifies
underlying myocardial pathology. We studied the relationship
between LV function and myocardial pathology in ESRF
patients with CMR. A total of 134 patients with ESRF
underwent CMR. LV function was assessed with further images
acquired after gadolinium-diethylentriaminepentaacetic
acid (DTPA). The presence of myocardial fibrosis was
indicated by late gadolinium enhancement (LGE). Two main
myocardial pathologies were identified. A total of 19 patients
(14.2%) displayed ‘subendocardial LGE’ representing
myocardial infarction, which was associated with
conventional cardiovascular risk factors including a history
of ischemic heart disease (IHD) (Po0.001),
hypercholesterolemia (Po0.05), and diabetes (Po0.01).
Patients with subendocardial LGE had greater LV mass
(Po0.05), LV dilation (Po0.01), and LV systolic dysfunction
(Po0.001) compared to patients with no evidence of LGE.
The second pattern, ‘diffuse LGE’, seen in 19 patients (14.2%)
appeared to represent regional areas of diffuse myocardial
fibrosis. Diffuse LGE was associated with greater LV mass
compared to patients without LGE (Po0.01) but not
systolic dysfunction. In total, 28.4% of all patients exhibited
evidence of myocardial fibrosis demonstrated by LGE. In
contrast to published literature describing three forms of
uremic cardiomyopathy – left ventricular hypertrophy (LVH),
dilation, and systolic dysfunction, we have shown that LVH is
the predominant cardiomyopathy specific to uremia, while
LV dilation and systolic dysfunction are due to underlying
(possibly silent) ischemic heart disease.
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Patients with end stage renal failure (ESRF) have a greatly
increased risk of premature cardiovascular events,1 in
particular sudden cardiac death. Although there is a high
prevalence of conventional cardiovascular risk factors in this
population, such as hypertension, diabetes, lipid abnorma-
lities, smoking, and inflammation, the relationship between
these factors and outcome is less clear than in the general
population. For example, inverse relationships exist between
both cholesterol and blood pressure and mortality in dialysis
patients.2,3 However by contrast, the presence of ‘uremic
cardiomyopathy’, described echocardiographically, defined as
the presence of left ventricular hypertrophy (LVH), dilation
and systolic dysfunction (LVSD), has been shown to be
strongly linked with poor cardiovascular outcome.4–7 Echo-
cardiography, although reliable and convenient, tends to
overestimate left ventricular (LV) mass in ESRF patients.8
While echocardiography provides valuable information on
myocardial dimensions, it affords less detail regarding
myocardial tissue composition. The uremic heart has been
associated with histological abnormalities, including increa-
sed interstitial myocardial fibrosis, described in post-mortem
specimens of patients with ESRF,9 as well as from endomyo-
cardial biopsies of patients on renal replacement therapy.10
Cardiovascular magnetic imaging provides a relatively
novel method for accurate definition of cardiac dimensions,
and is accepted as the ‘gold standard’ for the assessment of
ventricular dimensions.11 Previous studies have demon-
strated that this can be a useful tool in assessing cardiomyo-
pathy in patients with ESRF.8,12,13 Furthermore, using the
extracellular contrast agent gadolinium-diethylentriamine-
pentaacetic acid (Gd-DTPA), the presence of myocardial
fibrosis can be assessed. Contrast-enhanced cardiac magnetic
resonance (CMR) imaging has already been demonstrated to
provide additional insights into conditions associated with
deposition of fibrosis such as myocardial infarction,14
hypertrophic15 and dilated cardiomyopathy,16 as well
as acute inflammatory myocarditides,17 and other rarer
cardiomyopathies.18,19
By applying these techniques to study the heart in
ESRF, the relationship between LV geometry (with its prog-
nostic implications) and myocardial tissue damage can be
noninvasively assessed in detail. We therefore studied LV
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dimensions and function as well as myocardial composition
in patients with ESRF using CMR.
RESULTS
Left ventricular dimensions
A total of 134 patients underwent CMR (68.7% male; median
age 54 years, range 27–72). Baseline patient demographics
are shown in Table 1. There was a high prevalence of
conventional cardiovascular risk factors in this patient
group with 17.2% having a history of ischemic heart disease
(IHD), 23.9% of patients were diabetic (21.8% with diabetic
nephropathy), 38.1% had hypercholesterolemia, and 54.7%
had a positive smoking history.
The median LV mass was 172.3 g (interquartile range
(IQR) 67.8) and left ventricular mass index (LVMI) was
94.4 g/m2 (32.0). Overall, 11 (8.2%) patients had LVSD.
There was a correlation between LVMI and both systolic and
diastolic blood pressure (systolic blood pressure R¼ 0.329,
Po0.001; diastolic blood pressure R¼ 0.244, P¼ 0.005), but
no significant correlation was seen between time on renal
replacement therapy, or any other hematological or bio-
chemical markers. End diastolic volume and end systolic
volume also correlated with systolic blood pressure (R¼
0.322, Po0.001; R¼ 0.252, Po0.01, respectively) but not
diastolic blood pressure or any other hematological or
biochemical markers.
Description of results of late gadolinium enhancement
Overall, 38 (28.4%) patients had evidence of LGE at CMR. In
one patient, there was disparity between the two blinded
observers as to the presence of LGE. This image was reviewed
by a further independent observer and was considered LGE
negative, and analyzed as such. Patients who had evidence of
LGE (LGE positive) had greater LVMI (LGE positive –
median 104.0 g/m2, IQR 19.9; LGE negative – median 84.4 g/
m2, IQR 31.0, Po0.001), LV dilation (measured as end
diastolic volume: LGE positive – 152.5 ml, IQR 67.5; LGE
negative – 120.0 ml, IQR 56.8, Po0.001) and had greater
evidence of LVSD (ejection fraction: LGE positive – mean
63.6%, s.d. 13.8, LGE negative – mean 70.5%, s.d. 7.0,
P¼ 0.01) than patients with no LGE. Further analysis of the
pattern of LGE revealed crucial differences between patient
groups.
Broadly speaking, there were two patterns of LGE. Firstly,
discrete (subendocardial) LGE involving the subendocardium
was seen in 19 patients (14.2%). This finding is in keeping
with the pattern of LGE previously described in patients
with myocardial infarction and is shown in Figure 1a and b.
This finding was associated with conventional cardiovascular
risk factors and was found in significantly higher numbers in
patients with a history of IHD, hypercholesterolemia, and
diabetes but was not associated with gender, smoking history,
or a difference in blood pressure. While a history of IHD
was significantly associated with subendocardial LGE, nine
patients (6.7% of the whole study cohort, 47.3% of the
Table 1 | Baseline patient demographics
Variable All patients Gadolinium negative Gadolinium positive Subendocardial gadolinium Diffuse gadolinium
Number (%) 134 96 (71.6) 38 (28.4) 19 (14.2) 19 (14.2)
Age (years) 52.2710.4 51.5710.4 53.3710.0 55.679.6 51.6710.3
Sex (% male) 92 (68.7) 65 (67.7) 27 (71.1) 15 (78.9) 12 (63.2)
Hemodialysis (%) 93 (69.4) 72 (75) 21 (55.3)* 9 (47.4)* 12 (63.2)
Duration of RRT 12.0 (43.0) 12.0 (37.0) 12.0 (78.0) 12.0 (53.5) 21.0 (79.0)
History of IHD (%) 23 (17.2) 12 (12.5) 11 (28.9)* 10 (52.6)** 1 (5.3)
History of MI (%) 8 (5.8) 1 (1.0) 7 (19.4)*** 7 (36.8)** 0 (0)
Diabetes (%) 32 (23.9) 18 (18.8) 14 (36.8)* 11 (57.9)*** 3 (15.8)
Hypercholesterolemia (%) 51 (38.1) 36 (37.5) 15 (39.5) 11 (57.9)* 4 (21.1)
Smokers (%) 72 (53.7) 51 (51.3) 21 (55.3) 10 (52.6) 10 (52.6)
SBP (mmHg) 139.5725.1 138.9724.1 141.2727.8 145.1728.1 136.8727.6
DBP (mmHg) 81.8712.6 82.0712.3 81.1713.3 82.3712.4 79.8714.6
Cholesterol (mmol/l) 5.471.8 5.671.9 5.171.3 5.071.5 5.371.1
C-reactive protein (mmol/l) 15.0 (12.5) 7.0 (12) 12.0 (11.3) 12.5 (10.3) 12.0 (12.5)
Hemoglobin (g/dl) 11.871.7 11.771.7 12.071.6 12.271.4 11.971.9
Data are expressed as number with percent of specific subtype of late gadolinium enhancement in parenthesis; mean7standard deviation and median and intraquartile
range (in parenthesis) as appropriate. Abbreviations: RRT, renal replacement therapy; MI, myocardial infarction; IHD, ischemic heart disease; SBP, systolic blood pressure; DBP,
diastolic blood pressure. Tests of significance compared to patients with negative late gadolinium enhancement: *Po0.05, ***Po0.01, **Po0.001. w2 test and Fisher’s exact
test and parametric or non-parametric analysis of variance (as appropriate).
a b
Figure 1 | (a) Horizontal long axis view of the left ventricle of a
diabetic patient on peritoneal dialysis. There is a discrete area of
bright subendocardial late gadolinium enhancement (LGE) repre-
senting a large infero-lateral myocardial infarction (arrowed). Signal
intensity of this area is 44.0 compared to the 5.9 for the LGE-negative
area. (b) Short axis view of the same patient as (a). The
subendocardial gadolinium enhancement representing an inferior
myocardial infarction is arrowed.
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patients with subendocardial LGE) had CMR evidence of
myocardial infarction indicated by subendocardial LGE
despite no antecedent history of IHD. Description of the
clinical demographics of the patients with each type of LGE is
shown in Table 1.
The second pattern – diffuse LGE was less intense, without
subendocardial dominance. This diffuse LGE was seen in 19
patients (14.2%). While this pattern was still ‘patchy’ and was
therefore regional, this appears to represent regional areas
of diffuse fibrosis, within the left ventricle (Figure 2a and b).
There was no association between the presence of diffuse
LGE and the presence of cardiovascular risk factors, nor
was this associated with significant differences in time on
renal replacement therapy or blood pressure at the time of
scanning. These two patterns were not mutually exclusive and
one patient, with severe LVH, diabetes, and coronary artery
disease had both patterns of LGE.
Owing to the subjective nature of classification of pattern
of gadolinium enhancement, objective measurement was
made to compare signal intensity (or pixel intensity on the
analyzed images), of the region of interest of LGE compared
to that of nulled myocardium. The mean signal intensity
of nulled myocardium was 6.6 (s.d. 1.7), with that of sub-
endocardial LGE significantly higher than that of diffuse LGE
(32.7 SD 13.1 vs 18.6 s.d. 6.4, Po0.001), demonstrating
the distinct presence of diffuse LGE separate from any
artefact in the acquisition of images as well as the different
tissue properties of subendocardial and diffuse LGE (Table 2,
Figure 3).
Functional correlates of late gadolinium enhancement
Patients with subendocardial LGE had had greater LV mass,
LV dilation indicated by end diastolic volume, and poorer
systolic function indicated by reduced LV ejection fraction
Table 2 | Results of left ventricular dimensions and late gadolinium enhancement
Variable All patients
Gadolinium
negative
Gadolinium
positive
Subendocardial
gadolinium
Diffuse
Gadolinium
LVH (%) 96 (71.6) 61 (63.5) 35 (92.1)** 17 (89.5) * 18 (94.7)***
LV dilatation (%) 15 (11.2) 5 (5.2) 10 (27.7)*** 7 (36.8)*** 3 (15.8)
LVSD (%) 11 (8.2) 0 (0) 11 (57.9)** 8 (44.4)** 3 (15.8)**
EF (%) (s.d.) 68.579.9 70.577.0 63.6713.8* 59.7713.9** 67.5712.9
LV mass (g) 172.3 (67.8) 154 (64.0) 186.5 (50.8)** 185.0 (66.0)* 195 (47)***
LV mass/BSA (g/m2) 94.4 (32.0) 84.4 (31.0) 104.0 (19.9)** 100.5 (27.9) 105.0 (16.0)***
ESV (ml) 43.1 (30.2) 34.2 (21.5) 57.7 (41.7)** 64.0 (33.0)** 50.7 (34.3)*
ESV/BSA (ml/m2) 23.5 (14.0) 19.0 (12.5) 30 (21.9)** 35.5 (21.0)** 22 (17.9)
EDV (ml) 131.8 (64.6) 120 (56.8) 152.5 (67.5)** 174.0 (57.0)*** 140.0 (78.0)*
EDV/BSA (ml/m2) 71.9 (30.8) 69.0 (29.7) 84.0 (32.3)*** 89.6 (32.5)** 74.0 (31.8)
Mass of LGE — 0 9.074.9 9.376.2 8.773.4
Signal intensity of myocardium — 6.671.7 24.4712.3** 30.6713.6** 18.276.9**
Signal intensity index — 1 3.871.9 2.870.10** 5.371.8**
Normal angiogram (%) 20 (40.8) 13 (56.5) 7 (26.9) 0 (0) 7 (58.3)
No. of patients with mild/moderate CAD (%) 10 (20.4) 6 (26.1) 4 (15.4) 0 (0) 4 (33.3)
No. of patients with severe CAD (%) 19 (38.8) 4 (17.4) 15 (57.7)*** 14 (100)** 1 (8.3)
Data are expressed as number with percent of specific subtype of late gadolinium enhancement (LGE) in parenthesis; all data are median and intraquartile range (in
parentheses) except where mean7standard deviation are shown as appropriate. Percentages shown are as a proportion of that subtype of LGE and as percentage of patients
undergoing angiography with that subtype of LGE. Tests of significance compared to patients with negative LGE: *Po0.05, ***Po0.01, **Po0.001. Abbreviations: LVH, left
ventricular hypertrophy; LV, left ventricle/ventricular; LVSD, left ventricular systolic dysfunction; EF, ejection fraction; BSA, body surface area; EDV, end diastolic volume; ESV,
end systolic volume; LGE, late gadolinium enhancement; CAD, coronary artery disease.
a b
Figure 2 | (a) Short axis view of the left ventricle of hemodialysis
patient demonstrating a diffuse area of gadolinium
enhancement in the inferior wall of the left ventricle
(arrowed). Signal intensity of this area is 17.6 compared to the 6.9
for the LGE-negative area. (b) Short axis view of the left ventricle
of another hemodialysis patient demonstrating a diffuse area of
gadolinium enhancement in the lateral wall of the left ventricle.
Signal intensity of the area of late gadolinium enhancement is
32.0 compared to 8.4 for the LGE-negative area. This patient
had normal coronary arteries at angiography performed as
transplant assessment.
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Figure 3 | (a–b) Box plots demonstrating the mean signal
intensity (with 95% confidence intervals) for each area of
gadolinium enhancement. zPo0.001 compared to areas of
alternate patterns of LGE (paired samples t-test).
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compared to patients with no evidence of LGE. In these
patients it appears that myocardial interrogation using LGE
reveals that underlying ischemia, in particular myocardial
infarction, is the cause for cardiomyopathy. In patients with
subendocardial LGE, there was an inverse correlation
between mass of subendocardial LGE and LV ejection fraction
(Pearson’s R¼0.675, P¼ 0.002).
By contrast, patients with diffuse LGE had no or minimal
impairment of systolic function, compared to those without
LGE. However, diffuse LGE was associated with significantly
greater LV mass compared to patients without LGE, and
while the presence of LGE was also associated with a greater
LV dilatation indicated by increased end diastolic volume and
end systolic volume, this did not appear to have a negative
impact on systolic function, with no overall reduction
in ejection fraction. Unlike subendocardial LGE, there was
no significant correlation between the mass of diffuse LGE
and LV dimensions or function. In patients with diffuse
LGE, there was a trend towards a negative correlation between
overall LVMI and hemoglobin (Spearman’s R¼0.40,
P¼ 0.09), but no significant correlations with other biochem-
ical or hematological parameters. The functional character-
istics of the classifications of LGE are shown in Table 2.
Correlation of CMR with coronary angiography
In all, 49 patients underwent coronary angiography, of which
only 22 (40.8%) had normal coronary arteries (Table 2).
Patients with subendocardial LGE, consistent with previous
infarction, had a significantly higher burden of severe
coronary artery disease (Po0.001 compared to LGE-negative
patients). While more than half the patients with diffuse LGE
had normal coronary arteries, only one patient with diffuse
LGE had a significant stenosis in one vessel, suggesting that
diffuse LGE is unlikely to be directly linked to large vessel
coronary artery disease.
DISCUSSION
This is the first report using this technique to assess cardiac
function in patients with ESRF. We have used a widely
applied protocol,20 which represents a descriptive study using
CMR in ESRF to assess cardiac function and myocardial
tissue composition using Gd-DTPA to identify myocardial
fibrosis.
Published literature has categorized uremic cardiomyo-
pathy into three subtypes – LVH, ventricular dilatation, or
systolic dysfunction (or a combination of these patterns)4–7
with each pattern associated with cumulatively worse
survival.6 By contrast, we propose, based on CMR findings,
that there are only two types of uremic cardiomyopathy.
Firstly, that due to underlying IHD, where LV dilation and
systolic dysfunction are due primarily to previous myocardial
infarction revealed by CMR as subendocardial LGE. The
second form, diffuse LGE found in patients with more severe
LVH, is in keeping with a process, which we speculate may be
more specific to uremia and therefore represents a separate
entity.
Gadolinium-DTPA is an extracellular contrast agent
that diffuses into the interstitial space between cells and
exhibits its effect by shortening the T1 relaxation of tissue in
a magnetic field. There is greater space for Gd-DTPA
accumulation both in areas of myocardial fibrosis and
edema. In areas of ischemia or infarction, gadolinium leaks
into the surrounding fibrotic, or edematous, tissue resulting
in LGE on CMR imaging. However, the presence of LGE
is not specific and further subjective assessment of the
pattern of LGE is required. LGE has also been described in
patients with myocarditis,17 dilated cardiomyopathy,16 and
other cardiomyopathies.18,19 Importantly, LGE has been
shown to represent collagen deposition in hypertrophic
cardiomyopathy.15
We have demonstrated two patterns of LGE in patients
with ESRF. The first pattern – subendocardial LGE, consistent
with that described in myocardial infarction, follows a
primarily subendocardial distribution.20 This reflects the
perfusion of the sub-endocardium by end-arteries. Therefore,
we have shown a high prevalence of myocardial infarction in
our patient group indicated by subendocardial LGE. Patients
with subendocardial LGE had greater evidence of LV systolic
dysfunction, clearly highlighting the importance of under-
lying ischemic heart disease as the cause for ventricular
impairment in these patients. While this was associated with
a history of IHD, 6.7% of the patients studied had CMR
evidence of myocardial infarction, despite no preceding
history, in keeping with studies suggesting that ESRF patients
are likely to have silent myocardial ischemia.21 Although we
found more evidence of myocardial ischemia in patients on
peritoneal dialysis, this is likely to be due to the higher
number of diabetics on this modality (15.1% of hemodialysis
patients were diabetic compared to 43.9% on peritoneal
dialysis, w2 Po0.001).
The discovery of this high prevalence of myocardial
infarction in ESRF patients is important given the poor
long-term survival of these patients post infarction and
general trend towards under treatment in these patients.
Under use of cardioprotective therapy is common despite
the recognized benefits of secondary prevention in the
general population22–25; and with ongoing studies and emer-
ging evidence for cardioprotective drugs in ESRF.26–28 Thus,
the diagnosis of subclinical myocardial infarction with CMR
is likely to have prognostic and therapeutic implications
and may be an indication for further assessment with
angiography, particularly if the patient is being considered
for transplantation. Furthermore, in patients with coro-
nary artery disease requiring intervention, CMR can assess
myocardial viability prior to revascularization, allowing
optimal identification of patients likely to benefit from
coronary intervention.20
The second pattern of gadolinium enhancement demons-
trated was a pattern of diffuse, less intense, LGE. This was an
unexpected finding. This diffuse gadolinium enhancement is
less striking than that seen in, for example, myocardial
infarction or hypertrophic cardiomyopathy. However, it was
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reproducible and not due to artefact in the imaging process,
and was associated with features of uremic cardiomyopathy,
most notably LVH. Diffuse gadolinium enhancement implies
an additional pathological process, other than large vessel
myocardial infarction. It may reflect diminished capillary
blood supply with associated fibrosis,29 which is a prominent
histopathological finding in the uremic heart, or low-grade
ischemia.30 It may be that small vessel disease is also present
in patients who have epicardial atherosclerosis. Alternatively,
this pattern of enhancement may most likely represent
fibrosis throughout the hypertrophic ventricle, being evident
in severe hypertrophy. Overall, the presence of gadolinium
enhancement may not be because of a single process and to
address this issue a larger study of gadolinium enhancement
in patients with LVH because of hypertension and normal
renal function is necessary. There are common factors in the
development of hypertrophy and vascular disease in patients
with renal failure including hypertension, arterial stiffness,
vessel calcification,31 hyperparathyroidism,32 and anaemia.33
Although speculative, the association with gadolinium
enhancement with myocardial fibrosis is consistent with
histopathological reports of fibrosis in post-mortem speci-
mens of hypertrophic hearts of patients with ESRF.9
Uremic cardiomyopathy has been previously defined by
LV mass and chamber dimensions based on echocardio-
graphy. The echocardiographic assessment of chamber
volume and both calculated systolic function and LV mass
are highly dependent on the phase of dialysis cycle. Thus,
calculated LV mass may fall by approximately 10 g in post-
dialysis, compared to pre-dialysis assessment.13 CMR does
not have this limitation and previously we have been unable
to demonstrate significant systolic dysfunction in healthy
dialysis patients, although LVH is common,12 in keeping with
other studies showing only a slightly higher prevalence of
LVSD of 14.8% in unselected ESRF patients.6 In this study,
systolic dysfunction and ventricular dilatation are not present
in the absence of LGE and it is only patients with focal
gadolinium enhancement that have significant ventricular
dilatation and systolic dysfunction. This suggests that only
LVH is truly associated with uremia (and presumably is a
consequence of hypertension and other factors associated
with renal failure), while systolic dysfunction is not because
of uremia, but to underlying IHD. Therefore, CMR
represents an advance as additional investigation to guide
invasive assessment, particularly in asymptomatic patients,
undergoing evaluation for renal transplantation. The impli-
cation is that patients with systolic dysfunction require
investigation of coronary heart disease.
Our study has some limitations. We studied patients being
considered for renal transplantation, who are fitter than the
majority of patients with ESRF, and hence found a lower
prevalence of systolic dysfunction than expected. To fully
appreciate the burden of cardiovascular disease in patients
with ESRF, it would be necessary to study the entire dialysis
population. Therefore, we cannot exclude selection bias, and
expect a higher prevalence of LVSD (but also an even higher
prevalence of IHD) in an unselected cohort of dialysis
patients. Coronary angiography (and endomyocardial
biopsy) in all patients would provide additional information
regarding the relationship between LGE and coronary artery
disease, but is invasive, and as a pilot study direct correlation
with angiography was not sought. Hence, correlation
between angiographic and CMR findings should be inter-
preted with caution. Finally, in analysis of LGE, using signal
intensity, greater discrimination between nulled myocardium
and areas of LGE (using a signal intensity of LGE 42
standard deviations higher than the mean intensity of an area
of reference myocardium) would give greater distinction in
image analysis, but may exclude definite areas of LGE. Future
use of computer software to automatically detect areas of
LGE will optimize detection of enhancement.
In summary, CMR represents a novel method for detailed
investigation of myocardial function and tissue composition
in ESRF. By confirming a high burden of (potentially silent)
myocardial infarction indicated by subendocardial LGE,
we have demonstrated the importance of recognition
and treatment of atherosclerotic vascular disease in this
population and further investigation with angiography where
appropriate. By contrast, the presence of diffuse LGE suggests
that an additional process is present, perhaps specific to
uremia and related to fibrosis in the hypertrophic left
ventricle. Further study of this entity is required to assess its
clinical and pathological correlates, as well as CMR-based
studies with regression of LVH as a goal of treatment.
Moreover, the implications for survival merit investiga-
tion. With increasing availability, CMR may become a vital
instrument for the assessment of cardiovascular disease in
patients with ESRF and permits repeated non-invasive
screening during the long and uncertain wait for cadaveric
transplants.
MATERIALS AND METHODS
Patients
We prospectively studied 134 patients (median (range) age 54
(27–72) years; 67.6% male) with ESRF established on renal
replacement therapy, undergoing cardiological assessment prior to
consideration of renal transplant listing. All patients gave written,
informed consent and the study was approved by the local ethics
committee. All patients underwent conventional cardiovascular
risk factor assessment including history, clinical examination, ECG
as well as routine hematology, biochemical, and lipid profile.
A history of IHD was defined as previous myocardial infarction
or angina pectoris, and hypercholesterolemia was defined as fasting
total serum cholesterol 45.0 mmol/l or use of statin therapy. The
decision to list a patient for transplantation was not influenced by
CMR findings, and was taken on the basis of clinical findings and
additional investigations such as myocardial perfusion scanning and
coronary angiography as clinically indicated.
Exclusion criteria
Exclusion criteria were contraindications to magnetic resonance
scanning (permanent pacemaker, implanted ferromagnetic objects,
pregnancy, and extreme claustrophobia). We also screened and
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excluded two otherwise eligible patients with a documented history
or echocardiographic evidence of hypertrophic cardiomyopathy and
one further patient with a history of thalassemia and repeated
blood transfusions; both of which have been associated with charac-
teristic CMR findings.15,34 There was no evidence of other cause of
cardiomyopathy (e.g. amyloidosis, Fabry’s disease, sarcoidosis, iron
overload) in study patients based on clinical (original renal disease,
serum ferritin, and clinical review) and echocardiographic findings.
CMR technique
All patients underwent gadolinium CMR using a 1.5 Tesla MRI
scanner (Sonata, Siemens, Erlangan, Germany). CMR was per-
formed on the post–dialysis day in hemodialysis patients. Patients
on peritoneal dialysis were studied at their ‘dry weight’, according to
clinical charts. A fast imaging with steady-state precession (true
FISP) sequence was used to acquire cine images in long axis planes
(vertical long axis, horizontal long axis, left ventricular outflow
tract) followed by sequential short axis LV cine loops (8 mm
slice thickness, 2 mm gap between slices) from the atrioventicular
ring to the apex. Imaging parameters, which were standardized
for all subjects, included repetition time (TR)/echo time
(TE)/flip angle/voxel size/field of view (FoV)¼ 3.14 ms/1.6 ms/601/
2.2 1.3 8.0 mm/340 mm. Further images were acquired 10 min
after an intravenous bolus of Gd-DTPA (0.2 mmol/kg) using a
breath-hold segmented turbo fast low angle shot (FLASH)
inversion-recovery sequence, using identical slice positions as the
cines. Standardized settings were used for contrast-enhanced
imaging in all subjects. Specific parameters included TR/TE/flip
angle/voxel size/FoV/number of segments¼ 11.6 ms/4.3 ms/201/
2.2 1.3 8.0 mm/23. Inversion time for the TurboFLASH
sequence was optimized on an individual patient basis. Successful
nulling of normal myocardium was deemed to have been achieved
once the LV myocardium appeared black and homogenous. Gener-
ally, an inversion time of between 240 and 280 ms was required.
Overall, scan time was approximately 30–40 min.
Data analysis
LV function was analyzed by two observers, blinded to patient
clinical characteristics, from short axis cine loops using manual
tracing of epicardial and endocardial end-systolic and end-diastolic
contours with end-systolic and end-diastolic volumes and LV mass
calculated using analysis software (Argus, Siemens, Erlangen,
Germany). LVSD was defined as LV ejection fraction (LVEF)
o55%, with LVH defined as left ventricular mass index (LV mass/
body surface area; LVMI)484.1 g/m2 (male) or 476.4 g/m2
(female) and LV dilation defined as end diastolic volume/body
surface area 4111.7 ml/m2 (male) or 99.3 ml/m2 (female) or end
systolic volume 492.8 ml (male) or 70.3 ml (female) based on based
on mean normal LV dimensions for healthy volunteers plus 2
standard deviations.35
Contrast-enhanced image analysis
Myocardial fibrosis was documented as indicated by the presence of
LGE as previously described,14,15 with each image reviewed by two
blinded observers. Images were assessed for the presence, pattern,
and volume of gadolinium enhancement. Patients were classed as
having positive LGE, if LGE was seen on at least two (of three) views:
short axis view, long axis view, and reverse phase sequences, to
exclude artefact. Artefact on the contrast-enhanced images was
excluded by the acquisition of ‘reverse phase’ images through slice
planes which appeared to demonstrate intramyocardial contrast
enhancement. This technique involves the reversal of the phase-
encoding and frequency-encoding directions as the phase-encoding
direction is particularly prone to artefacts caused by cardiac motion
or chest wall movement. Only areas of contrast enhancement that
persisted on these reversed phase images were included in
subsequent quantification of areas of contrast enhancement.
Areas of contrast enhancement were first identified visually and
this area was contoured by manual planimetry to calculate volume
of enhanced myocardial tissue. Mean signal intensities (7s.d.) for
areas of contrast enhancement and for an adjacent reference area
of non-enhancing myocardium were then determined using the
Siemens Argus software. LGE was defined as an area of visually
identified contrast enhancement with a mean signal intensity that
was greater than one standard deviation higher than the mean signal
intensity of an adjacent area of reference ventricular myocardium,
which although nulled had a mean signal intensity significantly
above zero. No manual alteration of image brightness/intensity
settings was made during this process to ensure objective visual
assessment of LGE. We subsequently analyzed patterns of gadoli-
nium enhancement both subjectively and objectively based on mean
signal intensity. LGE volume was determined by manual planimetry
of any areas of contrast enhancement meeting these criteria. As
dynamic scaling occurs for all images, to ensure internal consistency
a mean signal intensity index was calculated as
Mean signal intensity index ¼
Mean intensity of region of LGE
Mean intensity of nulled myocardium
LGE mass was calculated by multiplying LGE volume by myocardial
density (1.05 g/cm3) and is used as the absolute measured value of
contrast-enhancing tissue seen.
Coronary angiography
A total of 49 patients underwent coronary angiography as part of
assessment for renal transplant listing. Decision to perform
angiography and interpretation of the angiogram was made by a
cardiologist blinded to CMR findings, and was made on clinical
grounds, based on symptoms, LVSD, or positive stress test (exercise
test or myocardial perfusion scanning). CMR was performed within
3 months (before or after) of angiography. Patients were classified as
having normal coronary arteries, mild/moderate coronary artery
disease (presence of coronary plaque or up to 70% stenosis of any
epicardial coronary artery), or severe coronary artery disease
(presence of 470% stenosis of any epicardial coronary artery).
Statistical analysis
We compared the prevalence of conventional cardiovascular risk
factors and LV abnormalities between those patients with, and
without, the presence of myocardial fibrosis indicated by CMR by w2
or Fisher’s exact test (as appropriate) for categorical data and paired
t-test and Mann–Whitney –U testing for parametric or non-
parametric data, respectively, for continuous data. Correlations
between LV structure and biochemical (corrected calcium, albumin,
glucose, cholesterol, urea reduction ratio in hemodialysis patients),
hematological (hemoglobin), and demographic (age, blood pres-
sure, time on renal replacement therapy) data were assessed using
Pearson and Spearman correlation coefficient for parametric and
non-parametric data, respectively. Analyses were performed using
SPSS Version 11.5 (SPSS Inc., Chicago, IL, USA).
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